TOFACITINIB

By Gary M. White, MD

Note, this is a brief summary only and is meant to emphasize dermatologic aspects. More complete information, including the package insert and recent studies should be consulted before prescribing.

Tofacitinib is a an oral Janus kinase inhibitor and is often given 5-10 mg po BID.

Adverse Events

Infection, e.g. herpes zoster.

Psoriasis

Oral tofacitinib 10 mg po BID for 24 weeks has efficacy similar to etanercept--59% PASI 75 at week 16 [British Journal of Dermatology 2015;173;949–961 and JAAD 2016;74;841.

Alopecia Areata

A patient with alopecia universalis grew all his hair with tofacitinib at 10 mg daily (J Invest Dermatol. 2014 Jun 18.).

Atopic Dermatitis

The Scoring of AD index decreased by 66.6% in 6 patients with AD treated with tofacitinib [JAAD 2015;73;395–399].

RegionalDerm

Homepage | FAQs | Use of Images | Contact Dr. White


It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.